A patient on nivolumab develops elevated TSH; what is the likely diagnosis?

Immune-Related Primary Hypothyroidism

The diagnosis is immune-related primary hypothyroidism secondary to nivolumab-induced thyroiditis. This is a well-recognized immune checkpoint inhibitor-related adverse event that occurs in approximately 12-20% of patients treated with nivolumab 1.

Pathophysiology and Clinical Pattern

Nivolumab blocks the PD-1 receptor, which disrupts immune tolerance mechanisms. Since normal thyroid tissue expresses PD-L1 and PD-L2, this blockade can trigger autoimmune destruction of the thyroid gland 2. The elevated TSH with presumed low or normal free T4 indicates primary thyroid failure rather than central (pituitary) dysfunction.

Key Diagnostic Features

The typical presentation follows one of two patterns:

Pattern 1: Biphasic thyroiditis (most common)

• Initial thyrotoxicosis phase develops within 4 weeks of starting nivolumab 2
• Transient hyperthyroid phase lasts approximately 4 weeks
• Rapid progression to hypothyroidism occurs within 16-32 days after the last low TSH 3
• Approximately one-third of patients follow this pattern 4

Pattern 2: Direct hypothyroidism

• TSH elevation without preceding thyrotoxicosis
• Can develop rapidly with TSH >50 mIU/L within 18-28 days of last normal value 3
• More common in patients without the initial inflammatory phase

Critical Diagnostic Workup

Immediately obtain:

• TSH and free T4 simultaneously 5 - this is essential because TSH alone can be misleading
• Morning cortisol and ACTH to exclude concomitant hypophysitis or adrenal insufficiency 5, 6

Why both tests matter: Low TSH with low FT4 indicates central hypothyroidism from hypophysitis, requiring different management. In hypophysitis, TSH can remain within normal range despite hypothyroidism 5. If there is any uncertainty about primary versus central hypothyroidism, hydrocortisone must be given before thyroid hormone replacement to avoid precipitating adrenal crisis 5.

Management Algorithm Based on Severity

Grade 1 (TSH 4.5-10 mIU/L, asymptomatic)

• Continue nivolumab without interruption 5
• Monitor TSH (with optional FT4) every 4-6 weeks 5
• No immediate treatment required

Grade 2 (TSH persistently >10 mIU/L or moderate symptoms)

• May continue or temporarily hold nivolumab until symptoms resolve 5
• Initiate levothyroxine replacement for:
  • Any symptomatic patient regardless of TSH level
  • Asymptomatic patients with TSH >10 mIU/L on two measurements 4 weeks apart 5
• Dosing considerations:
  • Patients <70 years without cardiac disease: start full replacement ~1.6 mcg/kg/day 5
  • Patients ≥70 years or with cardiac disease: start low at 25-50 mcg daily and titrate 5
• Monitor TSH every 6-8 weeks during titration; FT4 helps interpret abnormal TSH on therapy 5

Grade 3-4 (severe symptoms, life-threatening)

• Hold nivolumab immediately 5
• Urgent endocrinology consultation 5
• Hospital admission if myxedema suspected (bradycardia, hypothermia, altered mental status) 5, 7
• Critical: Give hydrocortisone before levothyroxine if any uncertainty about adrenal function 5

Important Clinical Pitfalls

Timing is rapid and unpredictable: Unlike traditional autoimmune thyroiditis, nivolumab-induced hypothyroidism develops within the first 3 months of treatment in most cases 3. TSH can rise from normal to >50 mIU/L in less than one month 3.

Recovery phase confusion: Elevated TSH may occur during recovery from thyrotoxicosis. In asymptomatic patients with normal FT4, consider monitoring for 3-4 weeks before treating, as spontaneous recovery can occur 5. However, progression or symptom development requires immediate treatment.

Thyroid antibodies are inconsistently positive: Only about 40-50% of patients have positive thyroid antibodies 2, 4, so their absence does not exclude the diagnosis.

Myxedema crisis is rare but life-threatening: Severe hypothyroidism can progress to myxedema crisis with altered mental status, hypothermia, and cardiovascular collapse 7. This requires ICU-level care with IV levothyroxine and stress-dose steroids.

Prognosis and Treatment Continuation

Hypothyroidism is typically permanent and requires lifelong levothyroxine replacement 2, 4. However, nivolumab can be safely continued or restarted once adequate thyroid hormone replacement is established 7. In patients with non-small cell lung cancer, development of thyroid dysfunction is associated with improved overall survival (HR 0.4, p=0.035) 4, suggesting it may be a marker of effective immune activation.

The diagnosis is straightforward when TSH is elevated with appropriate clinical context, but the key is recognizing the rapid evolution and ensuring both TSH and FT4 are checked to distinguish primary from central hypothyroidism before initiating treatment.